


**IN THE CLAIMS**

**WHAT IS CLAIMED IS:**


1. (CURRENTLY AMENDED) A compound of the formula:










and the pharmaceutically acceptable salts and solvates thereof, wherein:

A is selected from the group consisting of:


(1)















(2)









wherein the above rings of said A groups are substituted with 1 to 6 substituents each independently selected from the group consisting of:  $R^9$  groups, provided that when  $R^9$  is  $R^{13}$  then  $R^{13}$  is not H;


(3)






wherein one or both of the above rings of said A groups are substituted with 1 to 6 substituents each independently selected from the group consisting of: R<sup>9</sup> groups, provided that when R<sup>9</sup> is R<sup>13</sup> then R<sup>13</sup> is not H;

(4)





wherein the above phenyl rings of said A groups are substituted with 1 to 3 substituents each independently selected from the group consisting of: R<sup>9</sup> groups, provided that when R<sup>9</sup> is R<sup>13</sup> then R<sup>13</sup> is not H; and

(5)



B is selected from the group consisting of





n is 0 to 6;

p is 1 to 5;

X is O, NH, or S;


Z is 1 to 3;

R<sup>2</sup> is selected from the group consisting of: hydrogen, OH, -C(O)OH, -SH, -SO<sub>2</sub>NR<sup>13</sup>R<sup>14</sup>, -NHC(O)R<sup>13</sup>, -NHSO<sub>2</sub>NR<sup>13</sup>R<sup>14</sup>, -NHSO<sub>2</sub>R<sup>13</sup>, -NR<sup>13</sup>R<sup>14</sup>, -C(O)NR<sup>13</sup>R<sup>14</sup>, -C(O)NHOR<sup>13</sup>, -C(O)NR<sup>13</sup>OH, -S(O<sub>2</sub>)OH, -OC(O)R<sup>13</sup>, an unsubstituted heterocyclic acidic functional group, and a substituted heterocyclic acidic functional group; wherein there are 1 to 6 substituents on said substituted heterocyclic acidic functional group each substituent being independently selected from the group consisting of: R<sup>9</sup>




groups, and wherein the heterocyclic acidic functional group is selected from the group consisting of pyrrole, imidazole, triazole, and tetrazole;

each  $R^3$  and  $R^4$  is independently selected from the group consisting of: hydrogen, cyano, halogen, alkyl, alkoxy, cycloalkyl substituted with 1 to 4 alkyl groups wherein each alkyl group is independently selected, unsubstituted cycloalkyl, cycloalkyl substituted with 1 to 4 alkyl groups,  $-OH$ ,  $-CF_3$ ,  $-OCF_3$ ,  $-NO_2$ ,  $-C(O)R^{13}$ ,  $-C(O)OR^{13}$ ,  $-C(O)NHR^{17}$ ,  $-C(O)NR^{13}R^{14}$ ,  $-SO_{(t)}NR^{13}R^{14}$ ,  $-SO_{(t)}R^{13}$ ,  $-C(O)NR^{13}OR^{14}$ , unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl,




wherein there are 1 to 6 substituents on said substituted aryl group and each substituent is independently selected from the group consisting of:  $R^9$  groups; and wherein there are 1 to 6 substituents on said substituted heteroaryl group and each substituent is independently selected from the group consisting of:  $R^9$  groups; or

$R^3$  is and  $R^4$  taken together with the carbons atoms to which they are bonded to in the the phenyl B substituent



form a fused ring of the formula:



wherein  $Z^1$  or  $Z^2$  is an unsubstituted or substituted saturated heterocyclic ring (preferably a 4 to 7 membered heterocyclic ring), said ring  $Z^1$  or  $Z^2$  optionally containing one additional heteroatom selected from the group consisting of: O, S and  $NR^{18}$ ; wherein there are 1 to 3 substituents on said ring  $Z^1$  or  $Z^2$ , and each substituent is independently selected from the group consisting of: alkyl, aryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl,

heteroaryl, heteroarylalkyl, amino,  $-\text{C}(\text{O})\text{OR}^{15}$ ,  $-\text{C}(\text{O})\text{NR}^{15}\text{R}^{16}$ ,  $-\text{SO}_t\text{NR}^{15}\text{R}^{16}$ ,  $-\text{C}(\text{O})\text{R}^{15}$ ,  $-\text{SO}_2\text{R}^{15}$  provided that  $\text{R}^{15}$  is not H,  $-\text{NHC}(\text{O})\text{NR}^{15}\text{R}^{16}$ ,  $-\text{NHC}(\text{O})\text{OR}^{15}$ , halogen, and a heterocycloalkenyl group;

each  $\text{R}^5$  and  $\text{R}^6$  are the same or different and are independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy,  $-\text{CF}_3$ ,  $-\text{OCF}_3$ ,  $-\text{NO}_2$ ,  $-\text{C}(\text{O})\text{R}^{13}$ ,  $-\text{C}(\text{O})\text{OR}^{13}$ ,  $-\text{C}(\text{O})\text{NR}^{13}\text{R}^{14}$ ,  $-\text{SO}_{(t)}\text{NR}^{13}\text{R}^{14}$ ,  $-\text{C}(\text{O})\text{NR}^{13}\text{OR}^{14}$ , cyano, unsubstituted or substituted aryl, and unsubstituted or substituted heteroaryl group; wherein there are 1 to 6 substituents on said substituted aryl group and each substituent is independently selected from the group consisting of:  $\text{R}^9$  groups; and wherein there are 1 to 6 substituents on said substituted heteroaryl group and each substituent is independently selected from the group consisting of:  $\text{R}^9$  groups;

each  $\text{R}^7$  and  $\text{R}^8$  is independently selected from the group consisting of: H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heteroarylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl,  $-\text{CO}_2\text{R}^{13}$ ,  $-\text{CONR}^{13}\text{R}^{14}$ , alkynyl, alkenyl, and cycloalkenyl; and wherein there are one or more substituents on said substituted  $\text{R}^7$  and  $\text{R}^8$  groups, wherein each substituent is independently selected from the group consisting of:

- a) halogen,
- b)  $-\text{CF}_3$ ,
- c)  $-\text{COR}^{13}$ ,
- d)  $-\text{OR}^{13}$ ,
- e)  $-\text{NR}^{13}\text{R}^{14}$ ,
- f)  $-\text{NO}_2$ ,
- g)  $-\text{CN}$ ,
- h)  $-\text{SO}_2\text{OR}^{13}$ ,
- i)  $-\text{Si}(\text{alkyl})_3$ , wherein each alkyl is independently selected,
- j)  $-\text{Si}(\text{aryl})_3$ , wherein each alkyl is independently selected,
- k)  $-(\text{R}^{13})_2\text{R}^{14}\text{Si}$ , wherein each  $\text{R}^{13}$  is independently selected,
- l)  $-\text{CO}_2\text{R}^{13}$ ,


- m)  $-\text{C}(\text{O})\text{NR}^{13}\text{R}^{14}$ ,
- n)  $-\text{SO}_2\text{NR}^{13}\text{R}^{14}$ ,
- o)  $-\text{SO}_2\text{R}^{13}$ ,
- p)  $-\text{OC}(\text{O})\text{R}^{13}$ ,
- q)  $-\text{OC}(\text{O})\text{NR}^{13}\text{R}^{14}$ ,
- r)  $-\text{NR}^{13}\text{C}(\text{O})\text{R}^{14}$ , and
- s)  $-\text{NR}^{13}\text{CO}_2\text{R}^{14}$ ;

(fluoroalkyl is one non-limiting example of an alkyl group that is substituted with halogen);

$\text{R}^{8a}$  is selected from the group consisting of: hydrogen, alkyl, cycloalkyl and cycloalkylalkyl;

each  $\text{R}^9$  is independently selected from the group consisting of:

- a)  $-\text{R}^{13}$ ,
- b) halogen,
- c)  $-\text{CF}_3$ ,
- d)  $-\text{COR}^{13}$ ,
- e)  $-\text{OR}^{13}$ ,
- f)  $-\text{NR}^{13}\text{R}^{14}$ ,
- g)  $-\text{NO}_2$ ,
- h)  $-\text{CN}$ ,
- i)  $-\text{SO}_2\text{R}^{13}$ ,
- j)  $-\text{SO}_2\text{NR}^{13}\text{R}^{14}$ ,
- k)  $-\text{NR}^{13}\text{COR}^{14}$ ,
- l)  $-\text{CONR}^{13}\text{R}^{14}$ ,
- m)  $-\text{NR}^{13}\text{CO}_2\text{R}^{14}$ ,
- n)  $-\text{CO}_2\text{R}^{13}$ ,
- o)



- p) alkyl substituted with one or more  $-\text{OH}$  groups,

q) alkyl substituted with one or more  $\text{-NR}^{13}\text{R}^{14}$  group, and

r)  $\text{-N(R}^{13})\text{SO}_2\text{R}^{14}$ ;

each  $\text{R}^{10}$  and  $\text{R}^{11}$  is independently selected from the group consisting of  $\text{R}^{13}$ , halogen,  $\text{-CF}_3$ ,  $\text{-OCF}_3$ ,  $\text{-NR}^{13}\text{R}^{14}$ ,  $\text{-NR}^{13}\text{C(O)NR}^{13}\text{R}^{14}$ ,  $\text{-OH}$ ,  $\text{-C(O)OR}^{13}$ ,  $\text{-SH}$ ,  $\text{-SO}_t\text{NR}^{13}\text{R}^{14}$ ,  $\text{-SO}_2\text{R}^{13}$ ,  $\text{-NHC(O)R}^{13}$ ,  $\text{-NHSO}_2\text{NR}^{13}\text{R}^{14}$ ,  $\text{-NHSO}_2\text{R}^{13}$ ,  $\text{-C(O)NR}^{13}\text{R}^{14}$ ,  $\text{-C(O)NR}^{13}\text{OR}^{14}$ ,  $\text{-OC(O)R}^{13}$  and cyano;

$\text{R}^{12}$  is selected from the group consisting of: hydrogen,  $\text{-C(O)OR}^{13}$ , unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkylalkyl, and unsubstituted or substituted heteroarylalkyl group; wherein there are 1 to 6 substituents on the substituted  $\text{R}^{12}$  groups and each substituent is independently selected from the group consisting of:  $\text{R}^9$  groups;

each  $\text{R}^{13}$  and  $\text{R}^{14}$  is independently selected from the group consisting of: H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heteroarylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heterocyclic, unsubstituted or substituted fluoroalkyl, and unsubstituted or substituted heterocycloalkylalkyl (wherein "heterocycloalkyl" means heterocyclic); wherein there are 1 to 6 substituents on said substituted  $\text{R}^{13}$  and  $\text{R}^{14}$  groups and each substituent is independently selected from the group consisting of: alkyl,  $\text{-CF}_3$ ,  $\text{-OH}$ , alkoxy, aryl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,  $\text{-N(R}^{40})_2$ ,  $\text{-C(O)OR}^{15}$ ,  $\text{-C(O)NR}^{15}\text{R}^{16}$ ,  $\text{-S(O)}_t\text{NR}^{15}\text{R}^{16}$ ,  $\text{-C(O)R}^{15}$ ,  $\text{-SO}_2\text{R}^{15}$  provided that  $\text{R}^{15}$  is not H, halogen, and  $\text{-NHC(O)NR}^{15}\text{R}^{16}$ ; or

$\text{R}^{13}$  and  $\text{R}^{14}$  taken together with the nitrogen they are attached to in the groups  $\text{-C(O)NR}^{13}\text{R}^{14}$  and  $\text{-SO}_2\text{NR}^{13}\text{R}^{14}$  form an unsubstituted or substituted saturated heterocyclic ring, said ring optionally containing one additional heteroatom selected from the group consisting of: O, S and  $\text{NR}^{18}$ ; wherein there are 1 to 3 substituents on the substituted cyclized  $\text{R}^{13}$  and  $\text{R}^{14}$  groups and each substituent is independently selected from the group consisting of: alkyl, aryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, amino,  $\text{-C(O)OR}^{15}$ ,  $\text{-C(O)NR}^{15}\text{R}^{16}$ ,  $\text{-SO}_t\text{NR}^{15}\text{R}^{16}$ ,  $\text{-C(O)R}^{15}$ ,  $\text{-SO}_2\text{R}^{15}$  provided that  $\text{R}^{15}$  is not H,  $\text{-NHC(O)NR}^{15}\text{R}^{16}$ ,  $\text{-NHC(O)OR}^{15}$ , halogen, and a heterocycloalkenyl group;

each  $R^{15}$  and  $R^{16}$  is independently selected from the group consisting of: H, alkyl, aryl, arylalkyl, cycloalkyl and heteroaryl;

$R^{17}$  is selected from the group consisting of:  $-\text{SO}_2\text{alkyl}$ ,  $-\text{SO}_2\text{aryl}$ ,  $-\text{SO}_2\text{cycloalkyl}$ , and  $-\text{SO}_2\text{heteroaryl}$ ;

$R^{18}$  is selected from the group consisting of: H, alkyl, aryl, heteroaryl,  $-\text{C}(\text{O})\text{R}^{19}$ ,  $-\text{SO}_2\text{R}^{19}$  and  $-\text{C}(\text{O})\text{NR}^{19}\text{R}^{20}$ ;

each  $R^{19}$  and  $R^{20}$  is independently selected from the group consisting of: alkyl, aryl and heteroaryl;

$R^{30}$  is selected from the group consisting of: alkyl, cycloalkyl,  $-\text{CN}$ ,  $-\text{NO}_2$ , or  $-\text{SO}_2\text{R}^{15}$  provided that  $R^{15}$  is not H;

each  $R^{31}$  is independently selected from the group consisting of: unsubstituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl and unsubstituted or substituted cycloalkyl; wherein there are 1 to 6 substituents on said substituted  $R^{31}$  groups and each substituent is independently selected from the group consisting of: alkyl, halogen and  $-\text{CF}_3$ ;


each  $R^{40}$  is independently selected from the group consisting of: H, alkyl and cycloalkyl;

g is 1 or 2; and



t is 0, 1 or 2.

2. (CURRENTLY AMENDED) The compound of claim 1 wherein A is selected from the group consisting of:


(1) unsubstituted or substituted:



(2) substituted:




3. (ORIGINAL) The compound of Claim 1 wherein substituent A is:




wherein the furan ring is unsubstituted or substituted with 1 or 2 alkyl groups wherein each alkyl group is independently selected,  $R^7$  is selected from the group consisting of:  $-CF_3$ , alkyl and cycloalkyl, and  $R^8$  is H.


4. (ORIGINAL) The compound of Claim 1 wherein substituent A is:























wherein the furan ring is substituted with 1 or 2 alkyl groups independently selected from the group consisting of methyl, ethyl and isopropyl,  $R^7$  is selected from the group consisting of: ethyl, isopropyl and t-butyl, and  $R^8$  is H.


5. (CURRENTLY AMENDED) The compound of Claim 1 wherein A is selected from the group consisting of:














6. (ORIGINAL) The compound of claim 1 wherein A is selected from the group consisting of:




7. (ORIGINAL) The compound of Claim 1 wherein substituent A is selected from the group consisting of:




8. (ORIGINAL) The compound of Claim 1 wherein B is selected from the group consisting of:




9. (ORIGINAL) The compound of Claim 1 wherein B is selected from the group consisting of:




10. (ORIGINAL) The compound of Claim 1 wherein B is selected from the group consisting of:




11. (ORIGINAL) The compound of Claim 1 wherein B is selected from the group consisting of:



12. (ORIGINAL) The compound of Claim 1 wherein B is




13. (ORIGINAL) The compound of Claim 1 wherein B is:




wherein  $R^2$  is  $-OH$ .

14. (ORIGINAL) The compound of Claim 1 wherein B is:




wherein  $R^2$  is  $-OH$ , and  $R^{13}$  and  $R^{14}$  are independently selected from the group consisting of H and alkyl.

15. (ORIGINAL) The compound of Claim 1 wherein B is




16. (ORIGINAL) The compound of Claim 15 wherein R<sup>11</sup> is H.
17. (ORIGINAL) The compound of Claim 16 wherein R<sup>2</sup> is -OH.
18. (ORIGINAL) The compound of Claim 17 wherein R<sup>3</sup> is -C(O)NR<sup>13</sup>R<sup>14</sup>.
19. (ORIGINAL) The compound of Claim 17 wherein R<sup>3</sup> is -S(O)<sub>t</sub>NR<sup>13</sup>R<sup>14</sup>.
20. (ORIGINAL) The compound of Claim 1 wherein B is:




wherein R<sup>2</sup> is -OH, R<sup>3</sup> is -C(O)NR<sup>13</sup>R<sup>14</sup>, R<sup>11</sup> is H or methyl, and R<sup>13</sup> and R<sup>14</sup> are independently selected from the group consisting of: H, alkyl, unsubstituted cycloalkyl, substituted cycloalkyl, unsubstituted heteroaryl and substituted heteroaryl.

21. (ORIGINAL) The compound of Claim 1 wherein B is:



wherein R<sup>2</sup> is -OH, R<sup>3</sup> is -S(O)<sub>t</sub>NR<sup>13</sup>R<sup>14</sup>, R<sup>11</sup> is H or methyl, and R<sup>13</sup> and R<sup>14</sup> are independently selected from the group consisting of H, alkyl, unsubstituted cycloalkyl and substituted cycloalkyl.

22. (ORIGINAL) The compound of Claim 1 wherein B is:




23. (ORIGINAL) The compound of Claim 22 in R<sup>11</sup> is H.

24. (ORIGINAL) The compound of Claim 23 wherein R<sup>2</sup> is -OH.

25. (ORIGINAL) The compound of Claim 24 wherein R<sup>3</sup> is -C(O)NR<sup>13</sup>R<sup>14</sup>.


26. (ORIGINAL) The compound of Claim 24 wherein R<sup>3</sup> is -S(O)<sub>t</sub>NR<sup>13</sup>R<sup>14</sup>.

27. (ORIGINAL) The compound of Claim 1 wherein B is:



wherein R<sup>2</sup> is -OH, R<sup>3</sup> is -C(O)NR<sup>13</sup>R<sup>14</sup>, R<sup>11</sup> is H, and R<sup>13</sup> and R<sup>14</sup> are independently selected from the group consisting of: H, alkyl, unsubstituted heteroaryl and substituted heteroaryl.

28. (ORIGINAL) The compound of Claim 1 wherein B is:




wherein R<sup>2</sup> is -OH, R<sup>3</sup> is -S(O)<sub>t</sub>NR<sup>13</sup>R<sup>14</sup>, R<sup>11</sup> is H, and R<sup>13</sup> and R<sup>14</sup> are independently selected from the group consisting of H and alkyl.

29. (CURRENTLY AMENDED) The compound of Claim 1 wherein:


(1) substituent A in formula IA is selected from the group consisting of:

(a)




wherein the above rings are unsubstituted, or the above rings are substituted with 1 to 3 substituents independently selected from the group consisting of: F, Cl, Br, alkyl, cycloalkyl, and  $-\text{CF}_3$ ;  $\text{R}^7$  is selected from the group consisting of: H,  $-\text{CF}_3$ ,  $-\text{CF}_2\text{CH}_3$ , methyl, ethyl, isopropyl, cyclopropyl and t-butyl; and  $\text{R}^8$  is H; and

(b)




wherein the above ring is substituted with 1 to 3 substituents independently selected from the group consisting of: F, Cl, Br, alkyl, cycloalkyl, and  $-\text{CF}_3$ ;  $\text{R}^7$  is selected from the group consisting of: H,  $-\text{CF}_3$ ,  $-\text{CF}_2\text{CH}_3$ , methyl, ethyl, isopropyl, cyclopropyl and t-butyl; and  $\text{R}^8$  is H; and

(b) —



~~wherein  $\text{R}^7$  is selected from the group consisting of: H,  $-\text{CF}_3$ ,  $-\text{CF}_2\text{CH}_3$ , methyl, ethyl, isopropyl, cyclopropyl and t-butyl; and  $\text{R}^8$  is H; and  $\text{R}^{8a}$  is as defined in Claim 1;~~

(2) substituent B in formula IA is selected from the group consisting of:



wherein:

$R^2$  is selected from the group consisting of: H, OH,  $\text{-NHC(O)R}^{13}$  and  $\text{-NHSO}_2\text{R}^{13}$ ;

$R^3$  is selected from the group consisting of:  $\text{-C(O)NR}^{13}\text{R}^{14}$ ,  $\text{-SO}_2\text{NR}^{13}\text{R}^{14}$ ,  $\text{-NO}_2$ , cyano, and  $\text{-SO}_2\text{R}^{13}$ ;

$R^4$  is selected from the group consisting of: H,  $\text{-NO}_2$ , cyano, alkyl, halogen and  $\text{-CF}_3$ ;

$R^5$  is selected from the group consisting of: H,  $\text{-CF}_3$ ,  $\text{-NO}_2$ , halogen and cyano;


$R^6$  is selected from the group consisting of: H, alkyl and  $\text{-CF}_3$ ;


$R^{11}$  is selected from the group consisting of: H, halogen and alkyl; and

each  $R^{13}$  and  $R^{14}$  is independently selected from the group consisting of: H, unsubstituted alkyl.


30. (ORIGINAL) The compound of Claim 1 wherein:

(1) substituent A in formula IA is selected from the group consisting of:





(2) substituent B in formula IA is selected from the group consisting of:



wherein:

$R^2$  is  $-OH$ ;

$R^3$  is selected from the group consisting of:  $-SO_2NR^{13}R^{14}$  and  $-CONR^{13}R^{14}$ ;

$R^4$  is selected from the group consisting of: H, Br,  $-CH_3$ , ethyl and  $-CF_3$ ;

$R^5$  is selected from the group consisting of: H and cyano;


$R^6$  is selected from the group consisting of: H,  $-CH_3$  and  $-CF_3$ ;

$R^{11}$  is H; and




$R^{13}$  and  $R^{14}$  are independently selected from the group consisting of H and methyl.


31. (ORIGINAL) The compound of Claim 1 wherein substituent A is selected from the group consisting of:




and substituent B is selected from the group consisting of:



32. (ORIGINAL) The compound of Claim 1 wherein substituent A is selected from the group consisting of:



and substituent B is selected from the group consisting of:



33. (ORIGINAL) The compound of Claim 1 wherein g is 1.

34. (ORIGINAL) The compound of Claim 1 wherein g is 2.

35. (ORIGINAL) The compound of Claim 31 wherein g is 1.







36. (ORIGINAL) The compound of Claim 32 wherein g is 2.

37. (CURRENTLY AMENDED) A sodium, potassium, calcium, aluminum, gold, silver, N-methylglucamine, hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, or methanesulfonic ~~pharmaceutically acceptable~~ salt of a compound of Claim 1.













38. (ORIGINAL) A sodium salt of a compound of Claim 1.













39. (ORIGINAL) A calcium salt of a compound of Claim 1.











40. (CURRENTLY AMENDED) The A compound of ~~Claim 1~~ selected from the group consisting of:


















































































(a12)




pharmaceutically acceptable salts thereof, and pharmaceutically acceptable solvates thereof.


41. (CURRENTLY AMENDED) The compound of Claim [[1]] 40 selected from the group consisting of:




(a1)




(a2)




(a3)




(a4)




(a5)




(a6)




(a7)




(a8)




(a9)




(a10)




(a11)







(a12)



(a13)





(a14)





(a17)

(a18)




(a19)

(a20)




(a21)


(a22)




(a23)




(a24)




(a25)




(a26)




(a27)



(a28)




(a29)




(a30)







(a31)




(a32)




(a33)




(a34)




(a35)




(a36)




(a37)




(a38)









(a39)




(a40)




(a41)







(a47)




(a48)




(a49)



(a50)




(a51)




(a52)

pharmaceutically acceptable salts thereof, and pharmaceutically acceptable solvates thereof.


42. (CURRENTLY AMENDED) The compound of Claim 4 41 selected from the group consisting of compounds of the formula:




(a20)




(a21)





(a22)




(a23)




(a24)




(a25)




(a26)




(a27)




(a28)



(a29)



(a30)




(a31)




(a32)







(a33)




(a34)




(a35)




(a36)




(a37)




(a38)




(a39)




(a40)



(a41)




(a41)




(a42)







(a43)




(a44)




(a45)







(a46)



(a47)




(a48)




the pharmaceutically acceptable salts thereof, and the pharmaceutically acceptable solvates thereof.

43. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

44. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

45. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

46. (ORIGINAL) The compound of Claim 42 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

47. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

48. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

49. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

50. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

51. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

52. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

53. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

54. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

55. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

56. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

57. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

58. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

59. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

60. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

61. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

62. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

63. (ORIGINAL) The compound of Claim 41 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

64. (CURRENTLY AMENDED) The compound of Claim [[1]] 40 having the formula:




or a pharmaceutically acceptable salt or solvate thereof.

65. (CURRENTLY AMENDED) The compound of Claim [[1]] 40 having the formula:



or a pharmaceutically acceptable salt or solvate thereof.


66. (CURRENTLY AMENDED) The compound of Claim [[1]] 40 having the formula:



or a pharmaceutically acceptable salt or solvate thereof.



67. (CURRENTLY AMENDED) The compound of Claim [[1]] 40 having the formula:



or a pharmaceutically acceptable salt or solvate thereof.

68. Canceled (without prejudice).

69. Canceled (without prejudice).

70. (ORIGINAL) A pharmaceutical composition comprising at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with a pharmaceutically acceptable carrier.

71. (ORIGINAL) A pharmaceutical composition comprising at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, and at least one other agent, medicament, antibody and/or inhibitor for treating a chemokine mediated disease, in combination with a pharmaceutically acceptable carrier.

72. (ORIGINAL) A pharmaceutical composition comprising at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof, in combination with a pharmaceutically acceptable carrier.

73. (ORIGINAL) A pharmaceutical composition comprising at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof, and at least one other agent, medicament, antibody and/or inhibitor for treating a chemokine mediated disease, in combination with a pharmaceutically acceptable carrier.

74. Canceled (without prejudice).

75. Canceled (without prejudice).

76. Canceled (without prejudice).

77. Canceled (without prejudice).

78. Canceled (without prejudice).

79. Canceled (without prejudice).

80. Canceled (without prejudice).

81. Canceled (without prejudice).

82. Canceled (without prejudice).

83. Canceled (without prejudice).

84. Canceled (without prejudice).

85. Canceled (without prejudice).

86. (ORIGINAL) A method of treating multiple sclerosis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of glatiramer acetate, glucocorticoids, methotrexate, azothioprine, mitoxantrone, chemokine inhibitors, and CB2-selective inhibitors.

87. (ORIGINAL) A method of treating multiple sclerosis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group

consisting of: methotrexate, cyclosporin, leflunimide, sulfasalazine,  $\beta$ -methasone,  $\beta$ -interferon, glatiramer acetate, prednisone, etanercept, and infliximab.

88. (ORIGINAL) A method of treating rheumatoid arthritis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof.

89. (ORIGINAL) A method of treating rheumatoid arthritis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of COX-2 inhibitors, COX inhibitors, immunosuppressives, steroids, PDE IV inhibitors, anti-TNF- $\alpha$  compounds, MMP inhibitors, glucocorticoids, chemokine inhibitors, CB2-selective inhibitors, and other classes of compounds indicated for the treatment of rheumatoid arthritis.

90. (ORIGINAL) A method of treating stroke and cardiac reperfusion injury in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of thrombolitics, antiplatelet agents, antagonists, anticoagulants, and other compounds indicated for the treatment of rheumatoid arthritis.

91. (ORIGINAL) A method of treating stroke and cardiac reperfusion injury in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of tenecteplase, TPA, alteplase, abciximab, eptifibatide, and heparin.

92. (ORIGINAL) A method of treating psoriasis in a patient in need of such treatment, comprising administering to said patient a thereapeutically effective

amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of immunosuppressives, steroids, and anti-TNF- $\alpha$  compounds.

93. (ORIGINAL) A method of treating COPD in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof.

94. Canceled (without prejudice).

95. Canceled (without prejudice).

96. Canceled (without prejudice).

97. Canceled (without prejudice).

98. Canceled (without prejudice).

99. Canceled (without prejudice).

100. Canceled (without prejudice).

101. Canceled (without prejudice).

102. Canceled (without prejudice).

103. Canceled (without prejudice).

104. Canceled (without prejudice).

105. Canceled (without prejudice).

106. Canceled (without prejudice).

107. Canceled (without prejudice).

108. Canceled (without prejudice).

109. Canceled (without prejudice).

110. Canceled (without prejudice).

111. Canceled (without prejudice).

112. (ORIGINAL) A method of treating multiple sclerosis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of glatiramer acetate, glucocorticoids, methotrexate, azothioprine, mitoxantrone, chemokine inhibitors, and CB2-selective inhibitors.

113. (ORIGINAL) A method of treating multiple sclerosis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of: methotrexate, cyclosporin, leflunimide, sulfasalazine,  $\beta$ -methasone,  $\beta$ -interferon, glatiramer acetate, prednisone, etonercept, and infliximab.

114. (ORIGINAL) A method of treating rheumatoid arthritis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof.

115. (ORIGINAL) A method of treating rheumatoid arthritis in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 41, or a pharmaceutically

acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of COX-2 inhibitors, COX inhibitors, immunosuppressives, steroids, PDE IV inhibitors, anti-TNF- $\alpha$  compounds, MMP inhibitors, glucocorticoids, chemokine inhibitors, CB2-selective inhibitors, and other classes of compounds indicated for the treatment of rheumatoid arthritis.

116. (ORIGINAL) A method of treating stroke and cardiac reperfusion injury in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of thrombolitics, antiplatelet agents, antagonists, anticoagulants, and other compounds indicated for the treatment of rheumatoid arthritis.


117. (ORIGINAL) A method of treating stroke and cardiac reperfusion injury in a patient in need of such treatment comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of tenecteplase, TPA, alteplase, abciximab, eptifibatide, and heparin.

118. (ORIGINAL) A method of treating psoriasis in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof, in combination with at least one compound selected from the group consisting of immunosuppressives, steroids, and anti-TNF- $\alpha$  compounds.








119. (ORIGINAL) A method of treating COPD in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of at least one compound of Claim 41, or a pharmaceutically acceptable salt or solvate thereof.

120. Canceled (without prejudice).








- 121. Canceled (without prejudice).
- 122. Canceled (without prejudice).
- 123. Canceled (without prejudice).
- 124. Canceled (without prejudice).
- 125. Canceled (without prejudice).
- 126. Canceled (without prejudice)
- 127. Canceled (without prejudice)
- 128. Canceled (without prejudice).
- 129. Canceled (without prejudice).
- 130. Canceled (without prejudice)
- 131. Canceled (without prejudice)s.
- 132. (NEW) A compound selected from the group consisting of:















(Example 1)







Ex.	
2	
3	
4	
5	
6	
7	
8	



















9	
10	
11	
12	
13	
14	
15	








16	
17	
18	
19	
20	
21	








22	
23	
24	
25	
26	
27	

28	
29	
30	
31	
32	
33	







34	
35	
36	
37	
38	
39	
40	









41	
42	
43	
44	
45	
46	
47	
48	
49	










50	
51	
52	
53	
54	
55	
56	









57	
58	
59	
60	
61	
62	
63	



















64	
65	
66	
67	
68	
69	










70	
71	
72	
100	
101	
103	
104	
105	










106	
107	
108	
109	
110	
111	
112	
113	
114	

115	
116	
117	
118	
119	
120	
121	
122	








123	
124	
125	
126	
127	
128	
129	
130	








131	
132	
134	
135	
136	
137	
138	
139	








140	
141	
142	
143	
144	
145	
146	
147	
148	








149	
150	
151	
152	
153	
154	
155	
156	
157	







158	
159	
160	
161	
162	
163	
164	

165	
166	
167	
168	
169	
170	
171	


172	
173	
174	
175	
176	
177	
178	

179	
180	
181	
182	
183	
184	
185	


186	
187	
188	







(Example 200)













(Example 201)









(Example 201A)

Ex.	
201.1	
201.2	
201.3	
201.4	








201.5	
201.6	
201.7	
201.8	








201.9	
202	
203	
204	
205	
206	


















207	
208	
209	
210	
211	
212	






213	
214	
215	
216	
217	
218	
219	






220	
221	
222	
223	
224	
225	
226	

227	
228	
229	
230	
231	
232	
233	






234	
235	
236	
237	
238	
239	
240	







241	
241.1	
241.2	
241.3	
241.4	
242	
243	
244	







245	
246	
248	
249	
251	






252	
254	
255	
256	
257	









258	
259	
260	
262	
263	






264	
265	
266	
267	
268	
269	






270	
271	
272	
273	
274	
275	

276	
277	
278	
279	
280	







281	
282	
283	
284	
285	
286	







287	
289	
291	
292	
293	
294	






295	
296	
297	
298	
299	

300	
301	
302	
303	
304	













305	
306	
307	
308	
309	
310	






311	
312	
313	
314	
315	
316	

317	
318	
319	
320	
321	

322	
323	
324	
325	
326	





327	
328	
329	
330	
331	




332	
333	
334	
335	
336	





337	
338	
339	
340	
341	





342	
343	
344	
345	











346	
347	
348	
349	





350	
351	
352	
353	





354	
355	
356	
357	

358	
359	
360	
361	





362	
363	
364	
365	





366	
367	
368	
369	





370	
371	
372	
373	





374	
375	
376	
377	









378	
379	
380	
381	

382	
383	
384	
385	








386	 <chem>CC1=CC=C(C=C1O)N2C(=NS(=O)N2)N(C3=CC=C(C=C3)S(=O)(=O)N(C)C)C4=CC=C(C=C4)C</chem>
387	 <chem>CC(C)C1=CC=C(C=C1O)N2C(=NS(=O)N2)N(C3=CC=C(C=C3)S(=O)(=O)N(CC)CC)C4=CC=C(C=C4)C</chem>
388	 <chem>CC(C)C1=CC=C(C=C1O)N2C(=NS(=O)N2)N(C3=CC=C(C=C3)S(=O)(=O)N(CC)CC)C4=CC=C(C=C4)C</chem>
389	 <chem>CC(C)C1=CC=C(C=C1O)N2C(=NS(=O)N2)N(C3=CC=C(C=C3)S(=O)(=O)N(CC)CC)C4=CC=C(C=C4)C</chem>

390	
391	
392	
393	








394	
2001	
2002	
2003	
2004	
2005	









2006	
2007	
2008	
2009	
2010	
2011	
2012	








2013	
2014	
2015	
2016	
2017	
2018	
2019	







2020	
2021	
2022	
2023	
2024	
2025	
2026	














2027	
2028	
2029	
2031	
2032	
2033	
2034	








2035	
2036	
2037	
2038	
2039	
2040	
2041	
2042	






2043	
2044	
2045	
2046	
2047	
2049	
2050	

2051	
2052	
2053	
2054	
2055	
2056	

2057	
2058	
2059	
2060	
2062	
2063	






2064	
2065	
2066	
2067	
2068	






2069	
2070	
2071	
2072	
2073	
2074	
2075	






2076	
2077	
2078	
2079	
2080	













2081	
2082	
2083	
2084	
2085	



2086	
2087	
2088	
2089	
2090	

2091	
2092	
2093	
2094	
2095	

2096	
2097	
2098	
2099	
2100	

2101	
2102	
2103	
2104	
2105	

2106	
2107	
2108	
2109	
2110	

2111	
2112	
2113	<p style="text-align: center;">and</p> 